Journal
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
Volume 26, Issue 11, Pages 2603-2614Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jstrokecerebrovasdis.2017.06.023
Keywords
Permanent cerebral ischemia; STVNa; NF-kappa B; inflammatory; apoptosis
Categories
Funding
- Science and Technology Planning Project of Guangdong Province [2015B010109004]
- National Natural Science Foundation of China [31601089]
- Fundamental Research Funds for the Central Universities [2015ZM177]
- Open Project Program of Guangdong Key Laboratory of Fermentation and Enzyme Engineering, SCUT [FJ2015009]
Ask authors/readers for more resources
Background: Isosteviol sodium (STVNa) has been reported to have neuroprotective effects against ischemia/reperfusion (I/R) injury in rats. Furthermore, recanalization treatments, including thrombolytic therapy, have several limitations. Excessive inflammation and apoptosis contribute to the pathogenesis of ischemic brain damage. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) is critical to these processes and is associated with cerebral ischemia. Therefore, we studied the potential therapeutic effects and mechanisms of STVNa on permanent cerebral ischemia in mice. Methods: Permanent middle cerebral artery occlusion (pMCAO) was established via the suture method, followed by intravenous STVNa (7.5, 15, 30, 45, and 60 mg/kg). Neurobehavioral deficits, infarct volume, and histology were examined 24 hours after cerebral ischemia. In addition, the messenger RNA (mRNA) expression of NF-kappa B-related genes was detected using real-time quantitative polymerase chain reaction (qPCR). Results: STVNa (30 mg/kg) had significant neuroprotective effects 24 hours after pMCAO, including the reduction of the infarct volume and the improvement of the neurological severity score. Immunohistochemistry demonstrated that STVNa significantly increased the number of restored neurons and decreased the number of astrocytes. qPCR also demonstrated that the mRNA expression of inhibitor of nuclear factor kappa-B kinase-alpha, inhibitor of nuclear factor kappa-B kinase-beta, NF-kappa B, inhibitor of NF-kappa B-alpha, tumor necrosis factor-alpha, interleukin-1 beta, Bcl2-associated X protein, and caspase-3 were significantly downregulated, whereas B-cell CLL/lymphoma 2 mRNA was upregulated with STVNa treatment compared with vehicle. Conclusions: These findings demonstrate a neuroprotective role of STVNa during cerebral ischemia, which may result from interactions with the NF-kappa B signaling pathway and the associated inflammatory and apoptotic responses. (C) 2017 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available